<DOC>
	<DOCNO>NCT01908972</DOCNO>
	<brief_summary>The purpose study determine safety efficiency Propranolol initial treatment pediatric hemangioma .</brief_summary>
	<brief_title>The Safety Efficiency Propranolol Initial Treatment Pediatric Hemangioma</brief_title>
	<detailed_description>- Randomized ( A group : propranolol , B group : prednisolone ) - A group : 3 day admission medication 16 week - B group : medication 16 week without admission - Hemangioma volume comparison use MRI - measurement drug adverse reaction monitoring</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Hemangioma patient ( 0 ~ 9 month old ) No treatment 10 ~ 20 % volume increase 2 ~ 4 week Hemangioma cause organ function Hemangioma cause aesthetic problem Cardiovascular disease ( impossible use propranolol ) Drug adverse reaction allergy history ( propranolol , steroid ) Bradycardia , Atrioventricular block , atrial block Cardiogenic Shock Right heart failure ( pulmonary hypertension ) Congestive heart failure Hypotension Peripheral nerve disease ( moderate ) Angina Hormone deficiency patient Pulmonary disease ( asthma ) diabetic ketoacidosis laser treatment history</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Months</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hemangioma</keyword>
	<keyword>Propranolol</keyword>
	<keyword>prednisolone</keyword>
	<keyword>steroid</keyword>
</DOC>